STAT

FEBRUARY 21, 2024

Founded in 2011, Dario started with a diabetes app targeted at consumers before expanding it to hypertension and weight management. The move is a bet that a consolidated offering can attract a critical mass of large customers in a market where profits have been elusive.

Diabetes 302

Diabetes 302

Express Pharma

APRIL 27, 2023

Cipla holds a prominent position in the top five therapy areas in India, except for the anti-diabetes and gastrointestinal segment. Against this backdrop, the Indian pharma major is constantly partnering with multinational companies to get access to an innovative portfolio with a focus on diabetes, says GlobalData.

Diabetes 93

Diabetes 93

pharmaphorum

NOVEMBER 20, 2020

Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started dosing patients in a new study. It is due to generate results in December 2021, which could lead to filings in 2022.

Diabetes 98

Diabetes 98

ALiEM - Pharm Pearls

SEPTEMBER 20, 2024

A 50-year-old male with insulin-dependent Type 2 Diabetes presented to the emergency department with three days of pain and swelling on the right side of his neck. 2021 Oct;21(5):442-444. doi: 10.1136/practneurol-2021-002928. Epub 2021 May 7. Additional Images Physical Exam Vitals : BP 153/96; HR 110; T 100.0°F;

Diabetes 177

Diabetes 177

PharmD Live

DECEMBER 21, 2021

Virtual care, normalized by the pandemic, is now common practice for providers and patients, especially at the primary care level–a boon in 2021 for underserved chronic care populations. Aduhelm was approved by the FDA in 2021 with clinical trials outcome data indicating the potential to slow the accumulation of amyloid plaques.

Diabetes 52

Diabetes Hospitals 52

pharmaphorum

JANUARY 10, 2023

More than 100,000 people in England and Wales with type 1 diabetes that they find hard to control with current therapy could soon be offered new technology via the NHS. The decision follows a pilot study of closed-loop systems in 1,000 patients that got underway in 2021 at around 25 specialist centres across England.

Diabetes 69

Diabetes 69

PharmaShots

FEBRUARY 22, 2023

In 2021, the revenue of Trulicity increased by 28% in the U.S., Approved Indications of Trulicity2 Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients (age: ≥10 years) with type 2 diabetes mellitus. mL, 3 mg/0.5

Diabetes 64

Diabetes Compounding Dosage Communication 64

pharmaphorum

DECEMBER 23, 2020

Verily is planning “significant and focused growth” in 2021 after closing a $700 million funding round from investors including its parent company, and Google holding firm, Alphabet. 2021 will be a year of significant and focused growth for Verily’s operations as we continue to drive innovation in our core programmes.”.

Diabetes 59

Diabetes 59

European Pharmaceutical Review

FEBRUARY 6, 2025

The US Food and Drug Administration (FDA) has approved Genentechs Susvimo (ranibizumab injection) 100 mg/mL as the first treatment for diabetic macular oedema (DME) via continuous delivery. Susvimo demonstrated sustained vision improvements in diabetic macular oedema. letters, respectively).

Diabetes 52

Diabetes 52

BioPharma Dive

MARCH 29, 2023

The stock surge has made Biomea Fusion one of the sector’s top performers among the 130 biotechs that have gone public since the start of 2021.

Diabetes 70

Diabetes 70

pharmaphorum

JUNE 8, 2021

US healthcare group Carbon Health has made a move into digital care for patients with chronic conditions, buying diabetes-focused startup Steady Health. — Eren Bali (@erenbali) June 7, 2021. ” The post Carbon Health buys virtual diabetes clinic firm Steady Health appeared first on.

Diabetes 59

Diabetes Communication 59

ALiEM - Pharm Pearls

AUGUST 21, 2023

A 50-year-old male with a history of polysubstance use disorder and poorly-controlled type 2 diabetes mellitus presents with left hand pain. Risk factors for poor outcomes include immunocompromise (HIV, diabetes, immunosuppression), intravenous drug use, peripheral vascular disease, and polymicrobial infection. McGraw Hill; 2021.

Diabetes 130

Diabetes Hospitals 130

Pharma Marketing Network

MAY 12, 2021

This year, we are, and will continue to witness patients with chronic health conditions, like diabetes and hypertension, for example, make use of telehealth services. In 2021, telehealth is on track to continue to grow and tackle current barriers so that all people can gain greater access to their health care.

Diabetes 59

Diabetes 59

European Pharmaceutical Review

DECEMBER 15, 2022

At least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), mainly Africa, are set to benefit from Eli Lilly and Company and manufacturer EVA Pharmaceutical’s new collaboration delivering a sustainable supply of high-quality, affordable human and analogue insulin to this population.

Diabetes 97

Diabetes Packaging Communication 97

ALiEM - Pharm Pearls

AUGUST 18, 2023

The most common etiology of CN III palsy is ischemia of the nerve fibers secondary to diabetes mellitus or hypertension, which preferentially affects the internal somatic fibers that surround the blood supply. Case Question: What are the most common etiologies of the diagnosis? Oman J Ophthalmol. 2016 May-Aug;9(2):80-6.

Communication 130

Communication Diabetes 130

pharmaphorum

JANUARY 31, 2022

Glooko has made a name for itself in digital health circles with its data management tools for diabetes patients, and has now added artificial intelligence capabilities with an agreement to acquire xbird. The post Glooko adds AI to its digital diabetes tools with xbird takeover appeared first on. billion deal in 2020.

Diabetes 52

Diabetes 52

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. The post Provention finally gets FDA nod for type 1 diabetes drug teplizumab appeared first on.

Diabetes 52

Diabetes Immunization Immunity 52

pharmaphorum

NOVEMBER 15, 2021

It enrolled patients with and without type 2 diabetes and heart failure, to see whether treatment with Invokana (canagliflozin) can improve their symptoms, function and quality of life compared to placebo. billion in 2016 before the product was linked to an increased risk of lower limb amputation.

Diabetes 105

Diabetes Labelling 105

Eye on FDA

JANUARY 26, 2022

That said, the last two letters – the final one of 2021 and the first of 2022 both went to the same company – Lilly. There were additional limitations to the use of the drug, including that it is not recommended for people with severe stomach or intestinal problems, nor should it be used in people with type 1 diabetes.

Communication 108

Communication Diabetes 108

STAT

JULY 10, 2023

Around Thanksgiving 2021, Fernandez’s doctor approached him about trying something different: a new weight loss drug called Wegovy. But as stores and restaurants began to open up again, the numbers on his scale crept steadily higher. So did the number of fatty acids and excess sugar in his blood.

Communication 246

Communication Diabetes 246

pharmaphorum

MAY 5, 2021

After an indifferent period Novo Nordisk has kicked off 2021 on the front foot, raising its financial forecast after posting better than expected Q1 earnings and sales. The world’s biggest manufacturer of diabetes drugs expects growth in constant currencies at between 6% and 10%, up from the previous forecast in the 5%-9% range.

Diabetes 72

Diabetes Labelling 72

Express Pharma

AUGUST 23, 2024

The treatment of ABSSSI is further complicated by associated comorbidities such as diabetes, obesity, renal and hepatic dysfunction in these patients. per cent in 2021 ( S. Skin and soft tissue infections are the most common type of infections constituting, around 29-32 per cent of all infections in 2018-2019 in India.

Diabetes 105

Diabetes 105

pharmaphorum

AUGUST 6, 2021

The pandemic contributed to another 90,000 apps being introduced in 2020 – an average of 250 per day – and this coupled with rising number and functionality of wearable devices “provides evidence of digital health’s accelerating innovation,” according to the IQVIA Institute for Human Data Science’s 2021 trends report.

Diabetes 145

Diabetes 145

ALiEM - Pharm Pearls

SEPTEMBER 25, 2023

66 year-old-male with a history of type 2 diabetes and hypertension presented as a transfer for rapid progression of lower extremity pain, swelling, and blue-purple discoloration of the entire limb with concern for a possible necrotizing infection. 2021 Jun;36(5):392-400. He had no known thromboembolic risk factors. PMID: 33085284.

Medical Schools 152

Medical Schools Diabetes 152

Pharmaceutical Technology

JULY 15, 2022

The bill still must pass the Senate, and moreover, how uninsured people with diabetes will deal with steep prices still remains a question. CivicaRx is a non-profit generic drug company producing affordable insulin biosimilars in collaboration with the Juvenile Diabetes Research Foundation (JDRF). In-house manufacturing the norm.

Biosimilars 131

Biosimilars Diabetes Documentation Packaging 131

pharmaphorum

FEBRUARY 4, 2022

Lilly is a little vague on when it will now file donanemab with the FDA – suggesting on its fourth quarter 2021 results call that it may do so later this year – but reiterated that it has little hope of the drug being used ahead of the readout of TRAILBLAZER-ALZ 2 in mid-2023. Trulicity contributed $1.9

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes 98

pharmaphorum

JANUARY 4, 2021

Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody showed comparable results in diabetic macular oedema (DME) but with half the injections, in twin phase 3 studies. Roche is also testing the long-term safety and tolerability of faricimab in DME in the phase 3 Rhone-X study.

Diabetes 98

Diabetes 98

Pharmaceutical Technology

AUGUST 14, 2024

In 2021, the Centers for Disease Control and Prevention estimated that 49 percent of the U.S. population had either pre- or type 2 diabetes.

Diabetes 52

Diabetes 52

Pharmaceutical Technology

SEPTEMBER 7, 2022

The diabetic macular oedema (DME) market is anticipated to reach values of $11.1bn in 2031 across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan). The post Diabetic macular oedema market expected to grow to $11.1bn globally by 2031 appeared first on Pharmaceutical Technology.

Diabetes 52

Diabetes Biosimilars Labelling 52

pharmaphorum

JANUARY 17, 2022

Partnering with EraCal builds upon the success of Novo Nordisk’s Wegovy (semaglutide) chronic weight management drug, which was approved by the FDA in June 2021. Securing FDA approval was a huge development for the obesity space, marking the first approval for a weight management drug to be granted by the regulator since 2014.

Diabetes 123

Diabetes Pharmaceutical Companies Pharmaceutical Companies 123

Pharmaceutical Technology

NOVEMBER 30, 2022

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

The Thyroid Pharmacist

SEPTEMBER 2, 2022

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

Diabetes 98

Diabetes Health and Personal Care Stores Immunization Immunity 98

Pharmaceutical Technology

NOVEMBER 30, 2022

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes Labelling Communication 98

pharmaphorum

MARCH 3, 2022

It has been used to treat type 2 diabetes since 2014. So far, Farxiga has been cleared to treat type 2 diabetes and HFrEF only, although AZ has also stayed ahead of its rivals with an indication in chronic kidney disease. Lilly booked $1.5

Labelling 98

Labelling Diabetes Hospitals 98

pharmaphorum

JUNE 1, 2021

Novo Nordisk – which is already active in stem cell therapies with a candidate in early development for type 1 diabetes – is on the hook for up to $598 million in total licensing and milestone payments plus royalties on sales if HS-001 reaches the market. — Novo Nordisk (@novonordisk) June 1, 2021.

Immunization 138

Immunization Immunity Diabetes 138

Express Pharma

OCTOBER 16, 2024

Since the FDA approved Pfizer’s Comirnaty in August 2021, the first mRNA vaccine to achieve global market entry, rising licensing agreement values have reflected growing confidence in mRNA technology’s broader potential beyond vaccines, marking a pivotal shift in its applications across the pharmaceutical landscape.

Vaccines 104

Vaccines Immunization Immunity Diabetes 104

PharmaShots

JUNE 16, 2023

The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. This article is based on the 2021 biotech and pharma deals data as provided by Chris Dokomajilar of DealForma. 13, 2021 Deal Value: $1.7B 28, 2021 Deal Value: $1.9B

Immunization 40

Immunization Immunity Diabetes 40